The comparative safety of intravenous iron dextran, iron saccharate, and sodium ferric gluconate

Seminars in Dialysis

Volumn 13, Issue 6, 2000, Pages 381-384

  Fishbone, Steven ^a,b   Kowalski, Edward A ^a  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FERRIC GLUCONATE; FERRIC ION; FERRIC OXIDE, SACCHARATED; IRON DEXTRAN;

ANEMIA; COMPARATIVE STUDY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; RENAL REPLACEMENT THERAPY; REVIEW;

ANEMIA; FERRIC COMPOUNDS; HUMANS; INFUSIONS, INTRAVENOUS; IRON-DEXTRAN COMPLEX; RENAL DIALYSIS;

EID: 0034323822     PISSN: 08940959     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-139x.2000.00104.x     Document Type: Article

References (6)

1. Fishbone S, Frei GL, Maesaka J: Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 26:41-16, 1995
2. Silverberg DS, Blum M, Peer G, Kaplan F, laina A: Intravenous ferric saccharate as an iron supplement in dialysis patients. Nephron 72:413-417, 1996
3. Macdougall IC, Tucker B, Thompson J, Tomson CRV, Baker LRI, Raine AEG: A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 50:1694-1699, 1996
4. Granolleras C, Oules R, Branger B, Fourcade J, Shaldon S: Iron supplementation of hemodialysis patients receiving recombinant human erythropoietin therapy, in Erythropoietin: Molecular Physiology and Clinical Applications, edited by Bauer C, Koch KM, Scigalla P, Wieczorek L, New York, Marcel Dekker, 1993, pp 211-218
5. Taylor JE, Peat N, Porter C, Morgan AG: Regular, low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients. Nephrol Dial Transplant 11:1079-1083, 1996
6. Sunder-Plassmann G, Horl WH: Importance of iron supply for erythropoietin therapy. Nephrol Dial Transplant 10:2070-2076, 1995